TCRX insider transaction filings
TScan Therapeutics, Inc. — 24 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-05-22. Screen TCRX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-22 | 4 | Woods Keith — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Gruia Gabriela — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Klencke Barbara — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Nicholson Garry A — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Dorton Katina — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Bros. Advisors (GP) LLC — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director | Grant/award (A): 67,000 (derivative) @ $0 · Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | Dworak Leiden — See Remarks | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | Louis Chrystal — Chief Medical Officer | Grant/award (A): 420,000 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | ZDRAVESKI ZORAN — See Remarks | Grant/award (A): 350,000 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | MacBeath Gavin — Chief Executive Officer, Director | Grant/award (A): 1,165,000 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | Amello Jason — Chief Financial Officer | Grant/award (A): 350,000 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | Lynx1 Capital Management LP — 10% owner Nichols Weston — 10% owner | Purchase (P): 80,069 @ $0.90 · Purchase (P): 75,500 @ $0.90 · Purchase (P): 6,232 @ $0.90 | EDGAR |
| 2025-07-02 | 4 | Woods Keith — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Gruia Gabriela — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Klencke Barbara — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Nicholson Garry A — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Dorton Katina — Director | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Bros. Advisors (GP) LLC — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director | Grant/award (A): 67,000 (derivative) @ $0 · Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | Lynx1 Capital Management LP — 10% owner Nichols Weston — 10% owner | Purchase (P): 1,388,794 @ $1.20 · Purchase (P): 1,200,000 @ $1.20 | EDGAR |
| 2025-02-11 | 4 | Dworak Leiden | Grant/award (A): 46,875 (derivative) @ $0 | EDGAR |
| 2025-02-11 | 4 | Louis Chrystal — Chief Medical Officer | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2025-02-11 | 4 | ZDRAVESKI ZORAN — See Remarks | Grant/award (A): 52,500 (derivative) @ $0 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-02-11 | 4 | MacBeath Gavin — Chief Executive Officer, Director | Grant/award (A): 160,000 (derivative) @ $0 · Grant/award (A): 800,000 (derivative) @ $0 | EDGAR |
| 2025-02-11 | 4 | Amello Jason — Chief Financial Officer | Grant/award (A): 270,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — TScan Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-18 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-22 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TCRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →